Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL

NCT04582487 is registered in ClinicalTrials.gov with Gruppo Italiano Malattie EMatologiche dell'Adulto as lead sponsor.

NCT NCT04582487
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04582487 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL
Lead sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase
Not applicable
Overall status
Unknown status
Start date
May 19, 2021
Completion date
May 31, 2024
Enrollment
32 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

early t acute lymphoblastic leukemia, etp all, t acute lymphoblastic leukemia, t-lymphoblastic lymphoma